GL1X · GenesisL1 explorer

MolNFT v1 · #103138 · protein

Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634

4P7E · Tyrosine-protein kinase JAK2: “Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634”. X-ray diffraction, 1 ligand (2HB), 4 pockets (best druggability 0.74). MolNFT v1 #103138 on GenesisL1: 3D…

PDB
4P7E
Type
protein
Length
570 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein kinase JAK2
EC
2.7.10.2
UniProt
O60674
Ligands
2HB
Pockets
4 · best druggability 0.74

Structure

x-ray diffraction · 2 distinct chains · 44% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein kinase JAK2 (EC 2.7.10.2)protein28344% helix, 19% strandO60674
BTyrosine-protein kinase JAK2 (EC 2.7.10.2)protein28743% helix, 20% strandO60674

Ligands and binding sites

  • 2HB · N-(5-{4-[(1,1-dioxidothiomorpholin-4-yl) methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl) cyclopropanecarboxamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15840.740.81552HB
25250.720.81452HB
35930.680.7756empty
4560.310.7620empty

Interfaces

1 interface between chains.

  • A–B · 541 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 modified (phosphorylation).

Compared structures

  • 4P7E · Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to… · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.